Drew Cooper

Drew Cooper

Auto-generated profile, based on publicly available information

Drew Cooper

Brain Simulation Section, Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Diabetic Medicine
Verified
Journal Article
Open access
PDF file
CKChristine Knoll
Christine Knoll
SPSofia Peacock
Sofia Peacock
MWMandy Wäldchen
Mandy Wäldchen
DCDrew Cooper
Drew Cooper
SASimran Kaur Aulakh
Simran Kaur Aulakh
KBKatarina Braune
Katarina Braune
Aims: Several commercial and open‐source automated insulin dosing (AID) systems have recently been developed and are now used by an increasing number of people with diabetes (PwD). This systematic review explored the current status of real‐world evidence on the latest available AID systems in helping to understand their safety and effectiveness.Methods: A systematic review of real‐world studies on the effect of commercial and open‐source AID system use on clinical outcomes was conducted employing a devised protocol (PROSPERO ID 257354).Results: Of 441 initially identified studies, 21 published 2018–2021 were included: 12 for Medtronic 670G; one for Tandem Control‐IQ; one for Diabeloop DBLG1; two for AndroidAPS; one for OpenAPS; one for Loop; three comparing various types of AID systems. These studies found that several types of AID systems improve Time‐in‐Range and haemoglobin A1c (HbA1c) with minimal concerns around severe hypoglycaemia. These improvements were observed in open‐source and commercially developed AID systems alike.Conclusions: Commercially developed and open‐source AID systems represent effective and safe treatment options for PwD of several age groups and genders. Alongside evidence from randomized clinical trials, real‐world studies on AID systems and their effects on glycaemic outcomes are a helpful method for evaluating their safety and effectiveness.


26 September 2023 in Journal of Diabetes Science and Technology
Verified
Journal Article
Open access
DCDrew Cooper
Drew Cooper
BRBernd Reinhold
Bernd Reinhold
Arsalan ShahidArsalan Shahid
Arsalan Shahid
DLDana Lewis
Dana Lewis
Background: Open-source automated insulin delivery (OS-AID) systems combine commercially available insulin pumps and continuous glucose monitors with open-source algorithms to automate insulin dosing for people with insulin-requiring diabetes. Two data sets (OPEN and the OpenAPS Data Commons) contain anonymized OS-AID user data. Methods: We assessed glycemic variability (GV) outcomes in the OPEN data set and characterized it alongside a comparison to the n = 122 version of the OpenAPS Data Commons. Glucose data are analyzed using an unsupervised machine learning algorithm for clustering, and GV metrics are quantified using statistical tests for distribution comparison. Demographic data are also analyzed quantitatively. Results: The n = 75 OPEN data set contains 36 827 days worth of data. Mean TIR is 82.08% (TOR < 70: 3.66%; TOR > 180: 14.3%). LBGI ( P < .05) differs by gender whereas HBGI distributions are similar ( P > .05). GV metrics (except TOR < 70, LBGI) show a statistically significant difference ( P < .05) between data sets. Conclusions: Both the OPEN and OpenAPS Data Commons data sets show TOR < 70, TIR, and TOR > 180 within recommended goals, adding additional evidence of real-world efficacy of OS-AID. Future research should evaluate in more detail potential data set differences and relationships between individual patterns of user behaviors and GV outcomes.

6 January 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
BCBryan Cleal
Bryan Cleal
YCYanbing Chen
Yanbing Chen
MWMandy Wäldchen
Mandy Wäldchen
HBHanne Ballhausen
Hanne Ballhausen
DCDrew Cooper
Drew Cooper
KBKatarina Braune
Katarina Braune
Background: Although commercially developed automated insulin delivery (AID) systems have recently been approved and become available in a limited number of countries, they are not universally available, accessible, or affordable. Therefore, open-source AID systems, cocreated by an online community of people with diabetes and their families behind the hashtag #WeAreNotWaiting, have become increasingly popular. Objective: This study focused on examining the lived experiences, physical and emotional health implications of people with diabetes following the initiation of open-source AID systems, their perceived challenges, and their sources of support, which have not been explored in the existing literature. Methods: We collected data from 383 participants across 29 countries through 2 sets of open-ended questions in a web-based survey on their experience of building and using open-source AID systems. Narratives were thematically analyzed, and a coding framework was identified through iterative alignment. Results: Participants consistently reported improvements in glycemia, physical health, sleep quality, emotional impact on everyday life, and quality of life. Knowledge of open-source AID systems was largely obtained through the #WeAreNotWaiting community, which was also the primary source of practical and emotional support. The acquisition of the components to build an open-source AID system and the technical setup were sometimes problematic. Conclusions: The #WeAreNotWaiting movement represents a primary example of how informed and connected patients proactively address their unmet needs, provide peer support to each other, and obtain results through impactful, user-driven solutions. Alongside providing evidence on the safety and efficacy of open-source AID systems, this qualitative analysis helps in understanding how patients’ experiences and benefits range from psychosocial improvements to a reduction in the burden of managing diabetes. International Registered Report Identifier (IRRID): RR2-10.2196/15368

31 March 2022 in JMIR Diabetes
Verified
Journal Article
Open access
DCDrew Cooper
Drew Cooper
TUTebbe Ubben
Tebbe Ubben
CKChristine Knoll
Christine Knoll
HBHanne Ballhausen
Hanne Ballhausen
SOShane O'DOnnell
Shane O'DOnnell
DLDana Lewis
Dana Lewis
Background: People with diabetes and their support networks have developed open-source automated insulin delivery systems to help manage their diabetes therapy, as well as to improve their quality of life and glycemic outcomes. Under the hashtag #WeAreNotWaiting, a wealth of knowledge and real-world data have been generated by users of these systems but have been left largely untapped by research; opportunities for such multimodal studies remain open. Objective: We aimed to evaluate the feasibility of several aspects of open-source automated insulin delivery systems including challenges related to data management and security across multiple disparate web-based platforms and challenges related to implementing follow-up studies. Methods: We developed a mixed methods study to collect questionnaire responses and anonymized diabetes data donated by participants—which included adults and children with diabetes and their partners or caregivers recruited through multiple diabetes online communities. We managed both front-end participant interactions and back-end data management with our web portal (called the Gateway). Participant questionnaire data from electronic data capture (REDCap) and personal device data aggregation (Open Humans) platforms were pseudonymously and securely linked and stored within a custom-built database that used both open-source and commercial software. Participants were later given the option to include their health care providers in the study to validate their questionnaire responses; the database architecture was designed specifically with this kind of extensibility in mind. Results: Of 1052 visitors to the study landing page, 930 participated and completed at least one questionnaire. After the implementation of health care professional validation of self-reported clinical outcomes to the study, an additional 164 individuals visited the landing page, with 142 completing at least one questionnaire. Of the optional study elements, 7 participant–health care professional dyads participated in the survey, and 97 participants who completed the survey donated their anonymized medical device data. Conclusions: The platform was accessible to participants while maintaining compliance with data regulations. The Gateway formalized a system of automated data matching between multiple data sets, which was a major benefit to researchers. Scalability of the platform was demonstrated with the later addition of self-reported data validation. This study demonstrated the feasibility of custom software solutions in addressing complex study designs. The Gateway portal code has been made available open-source and can be leveraged by other research groups.

21 April 2023 in JMIR Preprints
Verified
Preprint
Open access
BCBryan Cleal
Bryan Cleal
YCYanbing Chen
Yanbing Chen
MWMandy Wäldchen
Mandy Wäldchen
HBHanne Ballhausen
Hanne Ballhausen
DCDrew Cooper
Drew Cooper
KBKatarina Braune
Katarina Braune
BACKGROUND Although commercially developed automated insulin delivery (AID) systems have recently been approved and become available in a limited number of countries, they are not universally available, accessible, or affordable. Therefore, open-source AID systems, cocreated by an online community of people with diabetes and their families behind the hashtag #WeAreNotWaiting, have become increasingly popular. OBJECTIVE This study focused on examining the lived experiences, physical and emotional health implications of people with diabetes following the initiation of open-source AID systems, their perceived challenges, and their sources of support, which have not been explored in the existing literature. METHODS We collected data from 383 participants across 29 countries through 2 sets of open-ended questions in a web-based survey on their experience of building and using open-source AID systems. Narratives were thematically analyzed, and a coding framework was identified through iterative alignment. RESULTS Participants consistently reported improvements in glycemia, physical health, sleep quality, emotional impact on everyday life, and quality of life. Knowledge of open-source AID systems was largely obtained through the #WeAreNotWaiting community, which was also the primary source of practical and emotional support. The acquisition of the components to build an open-source AID system and the technical setup were sometimes problematic. CONCLUSIONS The #WeAreNotWaiting movement represents a primary example of how informed and connected patients proactively address their unmet needs, provide peer support to each other, and obtain results through impactful, user-driven solutions. Alongside providing evidence on the safety and efficacy of open-source AID systems, this qualitative analysis helps in understanding how patients’ experiences and benefits range from psychosocial improvements to a reduction in the burden of managing diabetes. INTERNATIONAL REGISTERED REPORT RR2-10.2196/15368